199 related articles for article (PubMed ID: 28844493)
1. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
Forster M; Gehringer M; Laufer SA
Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
[TBL] [Abstract][Full Text] [Related]
2. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
[TBL] [Abstract][Full Text] [Related]
3. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
7. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
Dai J; Yang L; Addison G
Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
[TBL] [Abstract][Full Text] [Related]
8. Generation of a chemical genetic model for JAK3.
Remenyi J; Naik RJ; Wang J; Razsolkov M; Verano A; Cai Q; Tan L; Toth R; Raggett S; Baillie C; Traynor R; Hastie CJ; Gray NS; Arthur JSC
Sci Rep; 2021 May; 11(1):10093. PubMed ID: 33980892
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
He L; Shao M; Wang T; Lan T; Zhang C; Chen L
Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
[TBL] [Abstract][Full Text] [Related]
10. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.
Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA
J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
[TBL] [Abstract][Full Text] [Related]
13. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
14. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
[TBL] [Abstract][Full Text] [Related]
15. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
16. Discovery of highly potent, selective, covalent inhibitors of JAK3.
Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
[TBL] [Abstract][Full Text] [Related]
17. Development of Selective Covalent Janus Kinase 3 Inhibitors.
Tan L; Akahane K; McNally R; Reyskens KM; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K; Johannessen L; Akbay EA; Wong KK; Frank DA; Marto JA; Look TA; Arthur JS; Eck MJ; Gray NS
J Med Chem; 2015 Aug; 58(16):6589-606. PubMed ID: 26258521
[TBL] [Abstract][Full Text] [Related]
18. Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
Casimiro-Garcia A; Trujillo JI; Vajdos F; Juba B; Banker ME; Aulabaugh A; Balbo P; Bauman J; Chrencik J; Coe JW; Czerwinski R; Dowty M; Knafels JD; Kwon S; Leung L; Liang S; Robinson RP; Telliez JB; Unwalla R; Yang X; Thorarensen A
J Med Chem; 2018 Dec; 61(23):10665-10699. PubMed ID: 30423248
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
20. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
